Noninvasive In Vivo Thrombus Imaging in Patients With Ischemic Stroke or Transient Ischemic Attack—Brief Report

BACKGROUND: 18F-GP1 is a novel positron-emitting radiotracer that is highly specific for activated platelets and thrombus. In a proof-of-concept study, we aimed to determine its potential clinical application in establishing the role and origin of thrombus in ischemic stroke. METHODS: Eleven patients with recent ischemic stroke (n=9) or transient ischemic attack (n=2) underwent 18F-GP1 positron emission tomography and computed tomography angiography at a median of 11 (range, 2–21) days from symptom onset. 18F-GP1 uptake (maximum target-to-background ratio) was assessed in the carotid arteries and brain. RESULTS: 18F-GP1 uptake was identified in 10 of 11 patients: 4 in the carotid arteries only, 3 in the brain only, and 3 in both the brain and carotid arteries. In those with carotid uptake, 4 participants had >50% stenosis and 3 had nonstenotic disease. One case had bilateral stenotic disease (>70%), but only the culprit carotid artery demonstrated 18F-GP1 uptake. The average uptake was higher in the culprit (median maximum target-to-background ratio, 1.55 [interquartile range, 1.26–1.82]) compared with the contralateral nonculprit carotid artery (maximum target-to-background ratio, 1.22 [1.19–1.6]). In those with brain 18F-GP1 uptake (maximum target-to-background ratio, 6.45 [4.89–7.65]), areas of acute infarction on computed tomography correlated with brain 18F-GP1 uptake in 6 cases. Ex vivo autoradiography of postmortem infarcted brain tissue showed focal uptake corresponding to intraluminal thrombus within the culprit vessel and downstream microvasculature. There was also evidence of diffuse uptake within some of the infarcted brain tissue reflecting parenchymal petechial hemorrhage. CONCLUSIONS: 18F-GP1 positron emission tomography and computed tomography angiography is a novel noninvasive method of identifying in vivo cerebrovascular thrombosis, which holds major promise in understanding the role and origin of thrombosis in stroke. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03943966.

[1]  E. V. van Beek,et al.  Noninvasive In Vivo Coronary Artery Thrombus Imaging. , 2022, JACC. Cardiovascular imaging.

[2]  E. V. van Beek,et al.  18F-GP1 Positron Emission Tomography and Bioprosthetic Aortic Valve Thrombus. , 2022, JACC. Cardiovascular imaging.

[3]  M. Dweck,et al.  In vivo coronary artery thrombus imaging with 18F-GP1 PET-CT , 2021, European Heart Journal.

[4]  E. V. van Beek,et al.  In vivo Thrombosis Imaging in Patients Recovering from COVID-19 and Pulmonary Embolism. , 2021, American journal of respiratory and critical care medicine.

[5]  M. Dweck,et al.  Categorising myocardial infarction with advanced cardiovascular imaging , 2021, The Lancet.

[6]  M. Dichgans,et al.  Small vessel disease: mechanisms and clinical implications , 2019, The Lancet Neurology.

[7]  Jungsu S. Oh,et al.  Radiation dosimetry of [18F]GP1 for imaging activated glycoprotein IIb/IIIa receptors with positron emission tomography in patients with acute thromboembolism. , 2019, Nuclear medicine and biology.

[8]  Jungsu S. Oh,et al.  A phase 1, first-in-human study of 18F-GP1 positron emission tomography for imaging acute arterial thrombosis , 2019, EJNMMI Research.

[9]  N. Albert,et al.  Towards standardization of 18F-FET PET imaging: do we need a consistent method of background activity assessment? , 2017, EJNMMI Research.

[10]  N. Galldiks,et al.  18F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis , 2017, The Journal of Nuclear Medicine.

[11]  L. Dinkelborg,et al.  18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi , 2017, The Journal of Nuclear Medicine.

[12]  P. Rothwell,et al.  Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study , 2015, The Lancet Neurology.

[13]  Mary G. George,et al.  An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[14]  R. Virmani,et al.  Microvascular obstruction: underlying pathophysiology and clinical diagnosis. , 2010, Journal of the American College of Cardiology.

[15]  A. Konstas,et al.  Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies , 2006, Neuroradiology.

[16]  J M Wardlaw,et al.  Imaging appearance of the symptomatic perforating artery in patients with lacunar infarction: Occlusion or other vascular pathology? , 2001, Annals of neurology.

[17]  Michael Chopp,et al.  Measurement of cerebral microvessel diameters after embolic stroke in rat using quantitative laser scanning confocal microscopy , 2000, Brain Research.

[18]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.

[19]  J. Bamford,et al.  Classification and natural history of clinically identifiable subtypes of cerebral infarction , 1991, The Lancet.